Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Tumor Markers Quantified by Novel Technology

By LabMedica International staff writers
Posted on 30 Nov 2010
Two companies have signed a licensing agreement for a suite of clinical diagnostic assays for breast cancer based on quantitative immunohistochemistry (IHC). More...


HistoRx, Inc., (Branford, CT, USA) have signed a multiyear licensing agreement for their proprietary AQUA technology and several diagnostic assays with Genoptix, Inc., (Carlsbad, CA, USA).

Genoptix are launching their NexCourse breast cancer (BCa) assay by AQUA technology, which is more reproducible than traditional IHC testing for confidence in determining appropriate therapy. Moreover, the assay minimizes receptor status false-negative results by utilizing an objective, quantified score for protein expression that provides more accurate results. Genoptix obtained exclusive commercial laboratory rights in the US to develop and perform estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) assays using HistoRx's proprietary technology . The novel technology is ideal for confirmatory testing of ER/PR/HER2 status prior to hormonal therapy, antibody-based therapy, and/or chemotherapy when initial results are inconclusive or negative.

Misclassification of receptor status by IHC is common: several studies have shown that false-positive and false-negative ER/PR/HER2 results occur regularly in laboratories around the country and around the world. Inaccurate results may affect treatment decisions, excluding patients from use of potentially efficacious therapies or inappropriately subjecting patients to therapies known to cause serious adverse events.

Rana K. Gupta, CEO of HistoRx, said, "HistoRx is delighted to announce the first availability of AQUA technology for clinical diagnostics, and pleased that the breast cancer community will be the immediate beneficiaries of the quantification and reproducibility of measurement inherent in NexCourse BCa by AQUA technology. Genoptix has gained the trust of community oncologists and their patients by offering high quality laboratory testing, and HistoRx could not think of a more appropriate inaugural partner for commercialization of these assays.”

Related Links:

HistoRx, Inc.
Genoptix, Inc.




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.